 CAMBRIDGE, Mass., Dec. 08, 2020 GLOBE NEWSWIRE -- Sigilon Therapeutics, Inc. Nasdaq: SGTX, a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living TherapeuticsTM platform, today announced the closing of its upsized initial public offering of 8,050,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock, at a public offering price of 18.00 per share. The aggregate gross proceeds to Sigilon from the offering were 144.9 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were sold by Sigilon. Sigilons common stock is listed on The Nasdaq Global Select Market under the symbol SGTX. 